<DOC>
	<DOCNO>NCT00940784</DOCNO>
	<brief_summary>Clopidogrel ( Plavix ) aspirin two antithrombotic agent ( blood thinner ) commonly use patient previous thrombotic event ( stroke heart attack ) . Thrombosis formation blood clot blood vessel . Patients polycythemia vera routinely treat aspirin show effective reduce thrombotic risk . However , polycythemia vera patient previous thrombosis , benefit might obtain use combination aspirin clopidogrel routinely use patient recent acute myocardial ischemia ( reduce blood supply heart muscle ) . The study ass whether combination therapy greatly increase risk bleed versus aspirin alone , clopidogrel reduces biological factor might lead stroke heart attack , whether high number patient polycythemia vera resistant clopidogrel . Approximately 200 subject enrol Myeloproliferative Disorders-Research Consortium ( MPD-RC ) study Europe United States participation expect last 7 month ( 6 month receive study medication plus 30 day follow-up visit ) .</brief_summary>
	<brief_title>Clopidogrel Aspirin Treatment Polycythemia Vera</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Inclusion Criteria Patients include study follow criterion meet : 1 . A documented diagnosis polycythemia vera establish within 5 year registration . There must documentation patient met revise WHO criteria diagnosis polycythemia vera . Patients must meet 2 major criterion 1 minor criterion . To verify criterion meet , appropriate laboratory pathology report must submit demonstrate patient documentation diagnostic criterion . Major Criteria : Hemoglobin &gt; 18.5 g/dl men , &gt; 16.5 g/dl woman evidence increase red cell volume . Presence JAK2V617F functionally similar mutation JAK2 exon 12 mutation Minor Criteria : Bone marrow biopsy show hypercellularity age trilineage growth ( panmyelosis ) prominent erythroid , granulocyte , megakaryocytic proliferation . Serum erythropoietin level reference range normal . Endogenous erythroid colony formation vitro . 2 . High cardiovascular risk due experience prior vascular event ischemic stroke , myocardial infarction venous thromboembolism . Objective documentation event must accurately review registered . Stroke pulmonary embolism must document imaging study , deep vein thrombosis ultrasound objective method , myocardial infarction typical ECG change and/or increase serum troponin . Minor thrombotic event transient ischemic attack , superficial thrombophlepitis atypical microcirculatory disturbance alone combination consider qualifying event . 3 . No contraindication aspirin use allergy , history previous hemorrhagic stroke major gastrointestinal bleed previous three month . 4 . Use hydroxyurea cytoreductive agent . 5 . Signed informed consent : Patients must sign consent ISCLAP protocol mandatory correlative biomarker MPDRC 107 protocol order eligible . 6 . Serum bilirubin level less equal 2 time upper limit normal range laboratory ( ULN ) . 7 . Serum glutamicpyruvic transaminase ( SGPT ) alanine aminotransferase [ ALT ] ) level serum aspartate aminotransferase ( AST ) less equal 2 x ULN . 8 . Serum creatinine level less equal 1.5 x ULN . 9 . Women childbearing potential must negative serum urine pregnancy test prior clopidogrel treatment advise avoid become pregnant . Women childbearing potential must practice effective method contraception ( generally accept standard care measure ) . Women child bear potential woman menopausal 12 month undergone previous surgical sterilization . If subject woman childbearing potential , must use medically acceptable form contraception study period 30 day thereafter . 10 . Age great euql 18 year 81 year age . Exclusion Criteria Subjects exclude participate study 1 follow criterion meet : 1 . Therapy clopidogrel within last 12 month . 2 . Any history prior treatment aspirin result significant clinical adverse event require discontinuation aspirin therapy ( e.g . bleeding , GI intolerance , etc . intolerance aspirin . 3 . Patients require anticoagulation treatment warfarin , heparin low molecular weight heparin medical condition . 4 . Nursing pregnant female . Should woman become pregnant suspect pregnant participating study , inform physician immediately . 5 . History major bleed event ( require blood transfusion hospitalization , bleed critical site , lifethreatening ) . 6 . Clinical indication use clopidogrel and/or different antithrombotic regimen . 7 . History active substance alcoholic abuse within last year . 8 . Known hypersensitivity contraindication study treatment . 9 . Chronic viral hepatitis chronic liver disease cause associate MELD score equal high 8 . 10 . Presence disease ( e.g . cancer ) likely significantly shorten life expectancy . 11 . &gt; 81 year age 12 . New York Heart Association ( NYHA ) Grade II great congestive heart failure . 13 . A history gastrointestinal bleeding last 12 month . 14 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day , anticipation need major surgical procedure course study . 15 . Biopsy minor surgical procedure , exclude placement vascular access device bone marrow biopsy , within 7 day prior study enrollment . 16 . Ongoing serious , nonhealing wound , ulcer , bone fracture . 17 . Treatment CYP3A4 inhibitor , include azole antifungal ( topicals permit ) ; protease inhibitor ; nefazodone ; cyclosporine ; erythromycin ; clarithromycin ; troleandomycin . 18 . Serum AST great equal 2 x ULN Serum ALT great equal 2 x ULN Total Bilirubin great equal 2 X ULN Serum creatinine great equal 1.5 X ULN 19 . Patients diagnosis polycythemia vera &gt; 5 year time registration 20 . Patients high risk polycythemia vera define experience thrombotic event ( see section 3.1 ) occur since initial diagnosis PV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>